PHD1 regulates p53-mediated colorectal cancer chemoresistance

Overcoming resistance to chemotherapy is a major challenge in colorectal cancer (CRC) treatment, especially since the underlying molecular mechanisms remain unclear. We show that silencing of the prolyl hydroxylase domain protein PHD1, but not PHD2 or PHD3, prevents p53 activation upon chemotherapy...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:EMBO Mol Med
Päätekijät: Deschoemaeker, Sofie, Di Conza, Giusy, Lilla, Sergio, Martín-Pérez, Rosa, Mennerich, Daniela, Boon, Lise, Hendrikx, Stefanie, Maddocks, Oliver DK, Marx, Christian, Radhakrishnan, Praveen, Prenen, Hans, Schneider, Martin, Myllyharju, Johanna, Kietzmann, Thomas, Vousden, Karen H, Zanivan, Sara, Mazzone, Massimiliano
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Ltd 2015
Aiheet:
Research Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604688/
https://ncbi.nlm.nih.gov/pubmed/26290450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201505492
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia